Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DpC in Advanced Solid Tumors
NCT02688101Phase 1Completed
- Sponsor
- Vivat Therapeutics
- Start
- Apr 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DpC in solid tumor (advanced stage), sponsored by Vivat Therapeutics. Primary endpoint: Recommended Phase 2 Dose at 36 months. Started Apr 2016; status: completed.
02
Drugs
DpC
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02688101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688101.